The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers-Reference-Cited by-同舟云学术

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Published:2024-03-14 Issue:2 Volume:94 Page:157-167
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Dunn Allison,Takebe Naoko,Chen Alice,Kummar Shivaani,Piekarz Richard,Kiesel Brian,Moore Nancy,Doroshow James,Beumer Jan H.,Gobburu Jogarao V. S.

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00280-024-04651-x.pdf

Reference13 articles.

1. Gimsing P, Hansen M, Knudsen LM et al (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 81(3):170–176

2. Mackay HJ, Hirte H, Colgan T et al (2010) Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 46(9):1573–1579

3. Steele NL, Plumb JA, Vidal L et al (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14(3):804–810

4. 2017 Product Information: BELEODAQ(R) intravenous injection, belinostat intravenous injection. Spectrum Pharmaceuticals, Inc. (per FDA), Irvine, CA

5. Calvo E, Reddy G, Boni V et al (2016) Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies. Invest New Drugs 34(2):193–201